BIOGEN INC.
BIIBAPI behind this page
BIIB Q2 2025 request
Playground key active
/api/financials?ticker=BIIB&year=2025&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Revenue | 2,645.5 | 2,464.9 | +7.3% |
Show Product Lines breakouts |
|||
| Alzheimer's Collaboration | 54.9 | 11.8 | +365.3% |
| Alzheimer's collaboration revenue | 54.9 | 11.8 | +365.3% |
| AVONEX | 177.7 | 182.8 | -2.8% |
| AVONEX · Non Us | 56 | 65.6 | -14.6% |
| AVONEX · US | 121.7 | 117.2 | +3.8% |
| BENEPALI | 112.1 | 117.3 | -4.4% |
| BENEPALI · Non Us | 112.1 | 117.3 | -4.4% |
| Biosimilars | 181.7 | 198.1 | -8.3% |
| Biosimilars · Non Us | 179.2 | 187 | -4.2% |
| Biosimilars · US | 2.5 | 11.1 | -77.5% |
| BYOOVIZ | 8.6 | 13.7 | -37.2% |
| BYOOVIZ · Non Us | 6.1 | 3.4 | +79.4% |
| BYOOVIZ · US | 2.5 | 10.3 | -75.7% |
| Contract manufacturing revenue | 225 | 100 | +125.0% |
| FLIXABI | 14.3 | 13.1 | +9.2% |
| FLIXABI · Non Us | 14.3 | 13.1 | +9.2% |
| FUMADERM And ADUHELM | 0.4 | 2.7 | -85.2% |
| FUMADERM And ADUHELM · Non Us | 0.4 | 1.9 | -78.9% |
| Fumarate | 405.9 | 418 | -2.9% |
| Fumarate · Non Us | 170.7 | 229.7 | -25.7% |
| Fumarate · US | 235.2 | 188.3 | +24.9% |
| IMRALDI | 46.7 | 53.2 | -12.2% |
| IMRALDI · Non Us | 46.7 | 53.2 | -12.2% |
| Interferon | 246.7 | 250.9 | -1.7% |
| Interferon · Non Us | 96.7 | 105.5 | -8.3% |
| Interferon · US | 150 | 145.4 | +3.2% |
| MS Product Revenues | 1,107.2 | 1,149.8 | -3.7% |
| MS Product Revenues · Non Us | 449.8 | 567.4 | -20.7% |
| MS Product Revenues · US | 657.4 | 582.4 | +12.9% |
| Other | 46.8 | 17.6 | +165.9% |
| Other · Non Us | 0.4 | 1.9 | -78.9% |
| Other · US | 46.4 | 15.7 | +195.5% |
| PLEGRIDY | 69 | 68.1 | +1.3% |
| PLEGRIDY · Non Us | 40.7 | 39.9 | +2.0% |
| PLEGRIDY · US | 28.3 | 28.2 | +0.4% |
| Product | 1,878.7 | 1,899.6 | -1.1% |
| Product And Service Other | 244.6 | 109 | +124.4% |
| Product · Non Us | 937.6 | 1,052.9 | -11.0% |
| Product · US | 941.1 | 846.7 | +11.1% |
| QALSODY | 20 | 5 | +300.0% |
| QALSODY · Non Us | 12.5 | 0.4 | +3025.0% |
| QALSODY · US | 7.5 | 4.6 | +63.0% |
| Rare Disease Product Revenue | 543 | 534.1 | +1.7% |
| Rare Disease Product Revenue · Non Us | 308.2 | 296.6 | +3.9% |
| Rare Disease Product Revenue · US | 234.8 | 237.5 | -1.1% |
| Revenue from anti-CD20 therapeutic programs | 467.3 | 444.5 | +5.1% |
| Royalty | 19.6 | 9 | +117.8% |
| Royalty Attributed To OCREVUS | 353.8 | 336.3 | +5.2% |
| SKYCLARYS | 130.3 | 100 | +30.3% |
| SKYCLARYS · Non Us | 52.3 | 24.4 | +114.3% |
| SKYCLARYS · US | 78 | 75.6 | +3.2% |
| SPINRAZA | 392.7 | 429.1 | -8.5% |
| SPINRAZA · Non Us | 243.4 | 271.8 | -10.4% |
| SPINRAZA · US | 149.3 | 157.3 | -5.1% |
| TECFIDERA | 193.6 | 252.2 | -23.2% |
| TECFIDERA · Non Us | 146.4 | 208.1 | -29.6% |
| TECFIDERA · US | 47.2 | 44.1 | +7.0% |
| TYSABRI | 454.6 | 462.2 | -1.6% |
| TYSABRI · Non Us | 182.4 | 213.5 | -14.6% |
| TYSABRI · US | 272.2 | 248.7 | +9.4% |
| VUMERITY | 212.3 | 165.8 | +28.0% |
| VUMERITY · Non Us | 24.3 | 21.6 | +12.5% |
| VUMERITY · US | 188 | 144.2 | +30.4% |
| ZURZUVAE | 46.4 | 14.9 | +211.4% |
| ZURZUVAE · US | 46.4 | 14.9 | +211.4% |
Show Business Segments breakouts |
|||
| Reportable Segment | 2,645.5 | 2,464.9 | +7.3% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -22.9 | 7.6 | -401.3% |
| Cost of Revenue | 605 | 546 | +10.8% |
Show Product Lines breakouts |
|||
| Product · Reportable Segment | 415 | 358.4 | +15.8% |
| Royalty · Reportable Segment | 190 | 187.6 | +1.3% |
| Research And Development Expense Excluding Acquired In Process Cost | 399 | 505.4 | -21.1% |
Show Business Segments breakouts |
|||
| Reportable Segment · Early stage programs | 51.9 | 66.6 | -22.1% |
| Reportable Segment · Late stage programs | 44.6 | 46.7 | -4.5% |
| Reportable Segment · Marketed products | 87.7 | 170 | -48.4% |
| Reportable Segment · Research and discovery | 46.6 | 45.7 | +2.0% |
| Reportable Segment · Service Other | 168.2 | 176.4 | -4.6% |
| Research And Development Expense Including Acquired In Process Cost | 46.6 | 8.5 | +448.2% |
| Selling, General & Administrative | 583.8 | 553.8 | +5.4% |
| Amortization And Impairment Of Acquired Intangible Assets | 130.9 | 86.9 | +50.6% |
| Collaborationprofitlosssharing | 75 | 62.4 | +20.2% |
Show Schedule Of Equity Method Investment Equity Method Investee Name breakouts |
|||
| Samsung Bioepis | 57.2 | 55.9 | +2.3% |
Show Type Of Arrangement breakouts |
|||
| Sage Therapeutics | 17.8 | 6.5 | +173.8% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 13.2 | — | — |
| Restructuring Charges | -0.7 | 6.6 | -110.6% |
Show Income Statement Location breakouts |
|||
| Research And Development Expense · 2023 Cost Saving Initiatives | 1.3 | 2.2 | -40.9% |
| Research And Development Expense · Reata Integration | 4 | 3.3 | +21.2% |
| Restructuring Charges · 2023 Cost Saving Initiatives | -1.1 | 6.3 | -117.5% |
| Selling General And Administrative Expenses · 2023 Cost Saving Initiatives | 0.7 | 2 | -65.0% |
| Selling General And Administrative Expenses · Reata Integration | 1.8 | 1.5 | +20.0% |
Show Restructuring Cost And Reserve breakouts |
|||
| Employee Severance · 2023 and 2022 Cost Saving Initiatives | -0.7 | 6.6 | -110.6% |
Show Restructuring Plan breakouts |
|||
| 2023 Cost Saving Initiatives | 0.9 | 10.5 | -91.4% |
| Reata Integration | 5.8 | 5.1 | +13.7% |
| Other Operating Income Expense Net | 48.7 | 85.2 | -42.8% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | 0.1 | 0.2 | -50.0% |
| Total Costs & Expenses | 1,901.5 | 1,766.2 | +7.7% |
| Income Before Taxes | 744 | 698.7 | +6.5% |
| Income Tax Expense (Benefit) | 109.2 | 115.1 | -5.1% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | 1.8 | -0.3 | +700.0% |
| Net Income | 634.8 | 583.6 | +8.8% |
Show Business Segments breakouts |
|||
| Reportable Segment | 634.8 | 583.6 | +8.8% |
Show Reclassification Out Of Accumulated Other Comprehensive Income breakouts |
|||
| Reclassification Out Of Accumulated Other Comprehensive Income | -14.6 | 2.2 | -763.6% |
| EPS (Basic) | 4.33 | 4.01 | +8.0% |
| EPS (Diluted) | 4.33 | 4 | +8.3% |
| Wtd Avg Shares (Basic) | 146.5 | 145.6 | +0.6% |
| Wtd Avg Shares (Diluted) | 146.7 | 145.9 | +0.5% |
| Operating Expenses (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | 6.6 | -4.9 | +234.7% |
| Interest Income | -32.3 | -20.1 | -60.7% |
| Other Non-Operating Income (Expense) | 3.3 | 2 | +65.0% |
| Comprehensive Income | 571.2 | 598.1 | -4.5% |
| Other Comprehensive Income | -63.6 | 14.5 | -538.6% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 0.6 | — | — |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -105.8 | 20.1 | -626.4% |
| Accumulated Translation Adjustment | 41.6 | -5.6 | +842.9% |
| Foreign Currency Transaction Gain Loss Before Tax | 10.4 | 11.3 | -8.0% |
| Interest Expense | 72.6 | 61.3 | +18.4% |
Balance Sheet
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 2,758.8 | 1,908.9 | +44.5% |
| Accounts Receivable (Q) | — | — | — |
Show Related Party Transactions By Related Party breakouts |
|||
| Nonrelated Party | 1,624.2 | 1,627.1 | -0.2% |
| Related Party | 459.8 | 451.1 | +1.9% |
| Inventory | 2,274.3 | 2,506.1 | -9.2% |
| Other Assets Current | 850.6 | 615.3 | +38.2% |
| Total Current Assets | 7,967.7 | 7,108.5 | +12.1% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 3,098.8 | — | — |
| Operating Lease Right-of-Use Assets | 334.5 | 389.4 | -14.1% |
| Goodwill | 6,493.1 | 6,227.4 | +4.3% |
| Deferred Tax Assets | 330.9 | 915.1 | -63.8% |
| Other Non-Current Assets | 637.7 | 681.5 | -6.4% |
| Total Assets | 28,330.2 | 26,804.1 | +5.7% |
| Intangible Assets | 7,664.1 | 8,028.9 | -4.5% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 9,467.5 | 8,232.9 | +15.0% |
| Current Liabilities | |||
| Taxes Payable Current | 114.8 | 281.6 | -59.2% |
| Accounts Payable | 408.4 | — | — |
| Other Liabilities Current | 2,660.5 | — | — |
| Total Current Liabilities | 3,183.7 | 3,108.2 | +2.4% |
| Non-Current Liabilities | |||
| Long-Term Debt | 6,283.7 | 6,292 | -0.1% |
| Deferred Tax Liabilities | 118.3 | 590.6 | -80.0% |
| Operating Lease Liabilities | 310.9 | 367.5 | -15.4% |
| Other Non-Current Liabilities | 799.6 | — | — |
| Total Liabilities | 10,696.2 | 10,915 | -2.0% |
| Accrued Income Taxes Noncurrent | 165.1 | — | — |
| Stockholders' Equity | |||
| Common Stock | 0.1 | 0.1 | 0.0% |
| Additional Paid-In Capital | 714 | 407.5 | +75.2% |
| Accumulated Other Comprehensive Income | -238.1 | — | — |
| Retained Earnings | 20,135.1 | 18,604.6 | +8.2% |
| Treasury Stock Value | -2,977.1 | -2,977.1 | 0.0% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 17,634 | 15,889.1 | +11.0% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -238.1 | -146 | -63.1% |
| Additional Paid In Capital | 714 | 407.5 | +75.2% |
| Common Stock | 0.1 | 0.1 | 0.0% |
| Retained Earnings | 20,135.1 | 18,604.6 | +8.2% |
| Treasury Stock Common | -2,977.1 | -2,977.1 | 0.0% |
| Total Liabilities & Equity | 28,330.2 | 26,804.1 | +5.7% |
| Total Stockholders' Equity (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -15.6 | -2.7 | -477.8% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -112 | 9.8 | -1242.9% |
| Accumulated Other Comprehensive Income | -238.1 | -146 | -63.1% |
| Accumulated Translation Adjustment | -110.5 | -153.1 | +27.8% |
Cash Flow Statement
| Metric | YTD Q2 2025 | YTD Q2 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Net Income | 875.3 | 977 | -10.4% |
Show Equity Components breakouts |
|||
| Retained Earnings | 875.3 | 977 | -10.4% |
Show Business Acquisition breakouts |
|||
| Reata Pharmaceuticals, Inc · Fair Value Adjustment To Inventory | 103.9 | 134.2 | -22.6% |
| Depreciation & Amortization | 377.5 | 306.4 | +23.2% |
| Impairment Of Intangible Assets Indefinitelived Excluding Goodwill | 3.5 | — | — |
| Inventory Write Down | 14.3 | 44.4 | -67.8% |
| Amortization Of Inventory Step Up | 103.9 | 134.2 | -22.6% |
| Stock-Based Compensation | 155.9 | 143.4 | +8.7% |
| Deferred Income Taxes | -59.1 | -47.1 | -25.5% |
| Increase Decrease In Equity Securities Fv Ni | 33.2 | 61.6 | -46.1% |
| Other Non-Cash Items | 16 | 65 | -75.4% |
| Change in Accounts Receivable (YTD) | — | — | — |
Show Related Party Transactions By Related Party breakouts |
|||
| Nonrelated Party | -170.5 | 12.3 | -1486.2% |
| Related Party | 4.2 | -15.1 | +127.8% |
| Change in Inventory | -27.9 | -188.2 | +85.2% |
| Increase Decrease In Accrued Liabilities | -318.7 | -115.6 | -175.7% |
| Increase Decrease In Accrued Income Taxes Payable | -534.7 | -7.7 | -6844.2% |
| Increase Decrease In Other Operating Capital Net | -75.5 | -103 | +26.7% |
| Net Cash from Operations | 420.2 | 1,179 | -64.4% |
| Investing Activities | |||
| Capital Expenditures | -63.7 | -79.4 | +19.8% |
| Payments To Acquire Intangible Assets | -10 | -84.1 | +88.1% |
| Other Investing Activities | -30.6 | -3.3 | -827.3% |
| Net Cash from Investing | -104.3 | 400.5 | -126.0% |
| Financing Activities | |||
| Tax Withholding for Share Compensation | -18.2 | -40.8 | +55.4% |
| Proceeds From Issuance Of Long Term Debt | 1,733.4 | — | — |
| Repayments Of Long Term Debt | -1,750 | -650 | -169.2% |
| Proceeds From Payments For Other Financing Activities | 0.1 | 6 | -98.3% |
| Net Cash from Financing | -34.7 | -684.8 | +94.9% |
| Other Cash Flow | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | 281.2 | 894.7 | -68.6% |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 102.6 | -35.7 | +387.4% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.